Ixazomib as treatment for pyoderma gangrenosum associated with IgA smoldering multiple myeloma

Cespedes, David Alvarez; Gallitano, Stephanie M.; Bhutani, Divaya

doi:10.1007/s00277-021-04524-w

Cited by 3 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, ixazomib, a next generation oral proteasome inhibitor, was reported to be effective in a case of PG with concurrent IgA smoldering MM. Strikingly, a complete response was achieved in just a few weeks since initiation, paralleling the resolution of MGUS (76). Indeed, an aggressive management of HM aimed at the resolution of concomitant IgA MGUS has been advocated for to achieve PG remission (77).…”

Section: Dermal/hypodermal 231 Pyoderma Gangrenosum (Level Of Evidenc...mentioning

confidence: 99%

Neutrophilic and eosinophilic dermatoses associated with hematological malignancy

Maronese,

Derlino,

Moltrasio

et al. 2024

Front. Med.

View full text Add to dashboard Cite

Cutaneous manifestations of hematologic malignancy represent both a clinical challenge for the treating physician and a pathophysiological model for advancing the knowledge on individual neoplasms. Indeed, a growing body of evidence supports the concept of recurrent molecular defects associating with specific clinical features, as best exemplified by VEXAS. Herein neutrophilic and eosinophilic dermatoses of potential interest for both hematologists and dermatologists will be reviewed, including subcorneal pustular dermatosis-type IgA pemphigus, neutrophilic eccrine hidradenitis, Sweet’s syndrome as well as myelodysplasia cutis and VEXAS, pyoderma gangrenosum, eosinophilic annular erythema, eosinophilic dermatosis of hematological malignancy, Wells syndrome and cutaneous involvement in hypereosinophilic syndromes. Possible management approaches are discussed for each, emphasizing scenarios that require treatment of the underlying condition to achieve remission at the skin level.

show abstract

Section: Dermal/hypodermal 231 Pyoderma Gangrenosum (Level Of Evidenc...mentioning

confidence: 99%